DAM
TARS icon

DLD Asset Management’s Tarsus Pharmaceuticals TARS Stock Holding History

DLD Asset Management’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-32,500
Closed -$547K – 253
2022
Q1 		$547K Buy
+32,500
New +$603K 0.03% 145

Other funds holding TARS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DLD Asset Management's TARS Position: Q2 2022 in Review

DLD Asset Management sold out of Tarsus Pharmaceuticals (TARS) in Q2 2022, closing a stake of 32,500 shares — an estimated $547K sold.

DLD Asset Management first reported a position in TARS in Q1 2022 and held it in 1 quarter. The position peaked at $547K in Q1 2022. 73 funds tracked by Wall St. Rank hold TARS as of Q2 2022.

  • DLD Asset Management reported no remaining Tarsus Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • DLD Asset Management sold 32,500 Tarsus Pharmaceuticals shares in Q2 2022, an estimated $547K.
  • DLD Asset Management first reported a position in Tarsus Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • DLD Asset Management's Tarsus Pharmaceuticals position peaked at $547K in Q1 2022.
  • 73 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2022.

Based on DLD Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.